Botox to replace mascara?

Created by Allergan, the company behind the anti-wrinkle drug Botox, the new chemical for eyelashes, called Latisse, has been approved by the Food and Drug Administration (FDA) in the US. Latisse has been designed to treat a condition known as hypotrichosis of the eyelashes, which means a person does not have enough eyelashes, reports the Telegraph.

If applied once everyday to the eyelid using a disposable applicator, Latisse can apparently improve the length, thickness and colour of hairs. The drug should be used regularly to maintain the thicker lashes. Its side effects can include eye redness and itchiness, a darkening of the eyelid skin and a permanent darkening of the whites of the eyes.

The most important ingredient in Latisse is a chemical called a prostaglandin, which is present in hair. The chemical may help in the development and regrowth of hair follicles and is also used to treat glaucoma. In fact, it was a glaucoma specialist who first discovered the eyelash effect. Latisse, which is the first prescription product for lengthening eyelashes, will be available early next year and reportedly a 30-day supply of the drug will cost 120 dollars.

According to the company, the global sales of the drug could cross the figure of 300million pounds a year.

- TOI